CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
(WorldNews Switzerland)

-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent cell killing- ZUG, Switzerland and CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the presentation of new data from the company`s allogeneic chimeric antigen receptor T cell (CAR-T) program at the American Association for Cancer Research (AACR) Annual Meeting 2018. The data presented today demonstrate the generation of CAR-T cells...